Home LiteratureArticle Details
PMID: 9013391 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Review

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Journal of neural transmission (Vienna, Austria : 1996) ·Vol. 103 ·No. 8-9 ·1996-00-00 ·Pages 987-1041

Gerlach M, Riederer P

Abstract

Animal models are an important aid in experimental medical science because they enable one to study the pathogenetic mechanisms and the therapeutic principles of treating the functional disturbances (symptoms) of human diseases. Once the causative mechanism is understood, animal models are also helpful in the development of therapeutic approaches exploiting this understanding. On the basis of experimental and clinical findings. Parkinson's disease (PD) became the first neurological disease to be treated palliatively by neurotransmitter replacement therapy. The pathological hallmark of PD is a specific degeneration of nigral and other pigmented brainstem nuclei, with a characteristic inclusion, the Lewy body, in remaining nerve cells. There is now a lot of evidence that degeneration of the dopaminergic nigral neurones and the resulting striatal dopamine-deficiency syndrome are responsible for its classic motor symptoms akinesia and bradykinesia. PD is one of many human diseases which do not appear to have spontaneously arisen in animals. The characteristic features of the disease can however be more or less faithfully imitated in animals through the administration of various neurotoxic agents and drugs disturbing the dopaminergic neurotransmission. The cause of chronic nigral cell death in PD and the underlying mechanisms remain elusive. The partial elucidation of the processes underlie the selective action of neurotoxic substances such as 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), has however revealed possible molecular mechanisms that give rise to neuronal death. Accordingly, hypotheses concerning the mechanisms of these neurotoxines have been related to the pathogenesis of nigral cell death in PD. The present contribution starts out by describing some of the clinical, pathological and neurochemical phenomena of PD. The currently most important animal models (e.g. the reserpine model, neuroleptic-induced catalepsy, tremor models, experimentally-induced degeneration of nigrostriatal dopaminergic neurons with 6-OHDA, methamphetamine, MPTP, MPP+, tetrahydroisoquinolines, beta-carbolines, and iron) critically reviewed next, and are compared with the characteristic features of the disease in man.

MeSH Terms
Animals Behavior, Animal/drug effects Disease Models, Animal Dopamine/physiology Humans Neurotoxins Neurotransmitter Agents/physiology Oxidative Stress/physiology Parkinson Disease/pathology,physiopathology Parkinson Disease, Secondary/chemically induced,pathology,physiopathology
Chemicals
Neurotoxins Neurotransmitter Agents Dopamine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Gerlach M
Department of Clinical Neurochemistry, University Neurological Clinic, University of Würzburg, Federal Republic of Germany.
Riederer P
References (228)
228 references, click to expand
  1. Behavioural pharmacology of glutamate in the basal ganglia.
    J Neural Transm Suppl. 1992;38:65-89 PMID: 1491249
  2. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.
    J Neurochem. 1991 Apr;56(4):1441-4 PMID: 1900527
  3. Free radical-generated neurotoxicity of 6-hydroxydopamine.
    J Neurochem. 1995 Apr;64(4):1703-7 PMID: 7891098
  4. Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure.
    Science. 1969 Dec 5;166(3910):1284-6 PMID: 5350323
  5. Enzymatic oxidation of the dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, into 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion.
    Life Sci. 1995;57(11):1061-6 PMID: 7658913
  6. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.
    Eur J Pharmacol. 1991 Dec 12;208(4):273-86 PMID: 1815982
  7. Apoptosis and necrosis. Basic types and mechanisms of cell death.
    Arch Pathol Lab Med. 1993 Dec;117(12):1208-14 PMID: 8250690
  8. MRI, brain iron and experimental Parkinson's disease.
    J Neurol Sci. 1992 Dec;113(2):198-208 PMID: 1487755
  9. Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
    Life Sci. 1985 Jan 21;36(3):249-54 PMID: 3871245
  10. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.
    Nature. 1957 Nov 30;180(4596):1200 PMID: 13483658
  11. Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions.
    J Neural Transm Gen Sect. 1993;92(2-3):97-106 PMID: 7690233
  12. Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice.
    Arzneimittelforschung. 1993 Apr;43(4):413-5 PMID: 7684224
  13. Predicting Parkinson's disease.
    Nature. 1985 Sep 19-25;317(6034):198-9 PMID: 3876509
  14. Nigral and extranigral pathology in Parkinson's disease.
    J Neural Transm Suppl. 1995;46:15-31 PMID: 8821039
  15. A novel reaction time task for investigating force and time parameters of locomotor initiation in rats.
    Experientia. 1990 Oct 15;46(10):1084-8 PMID: 2226724
  16. Dopamine-derived 1-methyl-6,7-dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: in vivo and in vitro studies.
    J Neurochem. 1995 Jun;64(6):2635-43 PMID: 7760044
  17. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria.
    Biochem J. 1980 Nov 1;191(2):421-7 PMID: 6263247
  18. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.
    J Neural Transm. 1976;38(3-4):277-301 PMID: 956814
  19. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice.
    Eur J Pharmacol. 1993 Jun 4;236(3):487-9 PMID: 7689466
  20. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+).
    Neurosci Lett. 1990 Sep 4;117(1-2):129-33 PMID: 1981252
  21. Methamphetamine-induced neuronal damage: a possible role for free radicals.
    Neuropharmacology. 1989 Oct;28(10):1145-50 PMID: 2554183
  22. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine.
    Pharmacol Biochem Behav. 1984 Jul;21(1):29-31 PMID: 6431452
  23. Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
    Eur J Pharmacol. 1973 Mar;21(3):337-42 PMID: 4736076
  24. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
    Mol Chem Neuropathol. 1989 Jun;10(3):171-83 PMID: 2669769
  25. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
    Neuroscience. 1991;44(3):591-605 PMID: 1754053
  26. 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline, a new inhibitor of complex I.
    J Neural Transm Suppl. 1995;46:265-73 PMID: 8821063
  27. Striatal dopamine and homovanillic acid in Huntington's disease.
    J Neural Transm. 1986;65(2):151-5 PMID: 2939198
  28. In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP+, and MPP+.
    J Neural Transm Gen Sect. 1992;89(1-2):139-45 PMID: 1329855
  29. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.
    J Neural Transm. 1988;74(3):199-205 PMID: 3210014
  30. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
    J Neural Transm Park Dis Dement Sect. 1991;3(3):203-13 PMID: 1835581
  31. GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
    J Neurol Sci. 1990 Oct;99(1):59-68 PMID: 2250172
  32. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?--case of amantadine and memantine.
    J Neural Transm Park Dis Dement Sect. 1994;7(3):155-66 PMID: 7710668
  33. Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats.
    Brain Res. 1995 Oct 16;695(2):151-7 PMID: 8556325
  34. Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei.
    Neuropharmacology. 1980 Oct;19(10):989-95 PMID: 6106905
  35. Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Neurochem Int. 1990;17(2):263-70 PMID: 20504626
  36. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism.
    J Neurochem. 1992 May;58(5):1975-8 PMID: 1560246
  37. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.
    J Neural Transm Suppl. 1995;46:297-314 PMID: 8821067
  38. Haloperidol, catalepsy, and equilibrating functions in the rat: antagonistic interaction of clinging and labyrinthine righting reactions.
    Physiol Behav. 1981 Dec;27(6):1077-83 PMID: 7199742
  39. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.
    Exp Neurol. 1994 Nov;130(1):82-94 PMID: 7529713
  40. Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, Alzheimer disease, and neurologically normal controls.
    Mol Chem Neuropathol. 1993 Jan-Feb;18(1-2):133-44 PMID: 8466587
  41. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Proc Natl Acad Sci U S A. 1992 May 1;89(9):3859-63 PMID: 1570304
  42. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
    Ann Neurol. 1991 Nov;30(5):717-23 PMID: 1662477
  43. Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission.
    Neurosci Lett. 1995 Jul 28;195(1):9-12 PMID: 7478259
  44. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation.
    Biochem Pharmacol. 1989 Dec 1;38(23):4177-82 PMID: 2512934
  45. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
    Psychopharmacology (Berl). 1990;102(3):295-300 PMID: 1979176
  46. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain.
    Brain Res Bull. 1992 Nov;29(5):699-701 PMID: 1422867
  47. NMDA-dependent superoxide production and neurotoxicity.
    Nature. 1993 Aug 5;364(6437):535-7 PMID: 7687749
  48. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
    Neurosci Lett. 1985 Oct 24;61(1-2):195-200 PMID: 3878482
  49. Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier.
    Life Sci. 1988;42(23):2359-63 PMID: 3259663
  50. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats.
    J Neurochem. 1992 May;58(5):1979-982 PMID: 1560247
  51. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.
    Psychiatry Res. 1979 Dec;1(3):249-54 PMID: 298352
  52. The effect of repeated administration of methamphetamine on dopamine uptake sites in rat striatum.
    Neurosci Lett. 1994 Feb 14;167(1-2):37-40 PMID: 8177527
  53. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.
    J Neurochem. 1989 Feb;52(2):381-9 PMID: 2911023
  54. Motor disturbance induced by tremorine and oxotremorine.
    Naunyn Schmiedebergs Arch Pharmakol. 1970;267(1):80-98 PMID: 4393397
  55. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Brain Res. 1996 Nov 25;741(1-2):185-96 PMID: 9001722
  56. Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Potentiation by ascorbic acid.
    Mol Pharmacol. 1972 Mar;8(2):241-8 PMID: 5025202
  57. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity.
    Exp Neurol. 1995 Apr;132(2):279-83 PMID: 7789466
  58. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity.
    Naunyn Schmiedebergs Arch Pharmacol. 1979 Dec;310(2):185-7 PMID: 43481
  59. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
    Neurosci Lett. 1991 Feb 11;123(1):115-8 PMID: 1712088
  60. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study.
    Brain Res. 1994 Oct 10;660(1):8-18 PMID: 7828004
  61. Identification and quantification of 1,2,3,4-tetrahydro-beta-carboline, 2-methyl-1,2,3,4-tetrahydro-beta-carboline, and 6-methoxy-1,2,3,4-tetrahydro-beta-carboline as in vivo constituents of rat brain and adrenal gland.
    Biochem Pharmacol. 1981 Jan 1;30(1):9-17 PMID: 7213417
  62. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers.
    J Neurosci Res. 1993 May 1;35(1):67-82 PMID: 7685399
  63. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice.
    J Pharmacol Exp Ther. 1963 Jun;140:308-16 PMID: 13972348
  64. Brain peroxidase and catalase in Parkinson disease.
    Arch Neurol. 1975 Feb;32(2):114-8 PMID: 1122174
  65. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity.
    J Neurochem. 1994 Jun;62(6):2484-7 PMID: 8189253
  66. Functional role of the nigro-neostriatal dopamine neurons.
    Acta Pharmacol Toxicol (Copenh). 1966;24(2):263-74 PMID: 5297995
  67. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions.
    Science. 1970 Dec 11;170(3963):1212-3 PMID: 5478194
  68. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.
    Science. 1989 Jan 20;243(4889):398-400 PMID: 2563176
  69. Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products.
    Brain Res. 1990 Feb 12;509(1):125-33 PMID: 2137718
  70. Reactive oxygen species and the central nervous system.
    J Neurochem. 1992 Nov;59(5):1609-23 PMID: 1402908
  71. The catalepsy test: its ups and downs.
    Behav Neurosci. 1988 Oct;102(5):748-59 PMID: 2904271
  72. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats.
    J Neurochem. 1991 Dec;57(6):2133-5 PMID: 1940919
  73. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain.
    Brain Res. 1982 Mar 4;235(1):93-103 PMID: 6145488
  74. Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases.
    J Neural Transm. 1988;74(2):61-74 PMID: 2976808
  75. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
    Eur J Pharmacol. 1993 Apr 28;235(2-3):297-300 PMID: 7685291
  76. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro.
    Biochem Pharmacol. 1988 Dec 1;37(23):4573-4 PMID: 2849450
  77. Intranigral injected iron progressively reduces striatal dopamine metabolism.
    J Neural Transm Park Dis Dement Sect. 1994;8(3):209-14 PMID: 7748464
  78. Decreased catecholamines in the adrenal medulla of patients with parkinsonism.
    N Engl J Med. 1988 Jan 28;318(4):254 PMID: 3336415
  79. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
    Neuroscience. 1988 Jan;24(1):161-74 PMID: 3259295
  80. Hypokinesia produced by anterolateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs.
    Pharmacol Biochem Behav. 1978 Jan;8(1):41-5 PMID: 625480
  81. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
    Exp Neurol. 1994 Dec;130(2):269-78 PMID: 7867756
  82. Neurochemical lesioning in the rat brain with iontophoretic injection of the 1-methyl-4-phenylpyridinium ion (MPP+).
    Neurosci Lett. 1992 Jul 20;141(2):203-7 PMID: 1436635
  83. Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity.
    J Neural Transm Gen Sect. 1993;91(2-3):241-54 PMID: 8099799
  84. Effect of oxidative stress on excitatory amino acid release by cerebral cortical synaptosomes.
    Free Radic Biol Med. 1993 Dec;15(6):671-5 PMID: 7908006
  85. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Mov Disord. 1989;4(1):53-74 PMID: 2494438
  86. Secondary (toxic) parkinsonism as model of Parkinson's disease.
    Funct Neurol. 1988 Oct-Dec;3(4):449-57 PMID: 3072280
  87. Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine.
    J Neural Transm Park Dis Dement Sect. 1989;1(4):317-22 PMID: 2557047
  88. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde.
    Life Sci. 1987 Mar 2;40(9):827-32 PMID: 2434820
  89. 1-Methyl-4-phenylpyridine (MPP+): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation.
    Eur J Pharmacol. 1986 Nov 19;131(2-3):199-209 PMID: 3493157
  90. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice.
    J Neurochem. 1994 Jan;62(1):380-3 PMID: 7505315
  91. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
    Neurosci Lett. 1985 Apr 9;55(2):179-84 PMID: 2582318
  92. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement.
    J Neurochem. 1992 Feb;58(2):786-9 PMID: 1729421
  93. Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats.
    J Neural Transm Suppl. 1995;46:283-9 PMID: 8821065
  94. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice.
    J Neurosci. 1990 Jun;10(6):1912-21 PMID: 1972393
  95. Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat.
    Neurosci Lett. 1994 Mar 28;170(1):191-4 PMID: 8041505
  96. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies.
    Brain Res. 1996 Feb 19;709(2):285-95 PMID: 8833765
  97. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons.
    Eur J Pharmacol. 1968 Dec;5(1):107-10 PMID: 5718510
  98. Effects of MPTP, MPP+ and paraquat on mitochondrial potential and oxidative stress.
    Life Sci. 1989;44(18):1277-84 PMID: 2785626
  99. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
    Neurosci Lett. 1988 Oct 5;92(2):228-33 PMID: 3263594
  100. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Neurodegeneration. 1995 Sep;4(3):257-69 PMID: 8581558
  101. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.
    J Neurochem. 1995 Feb;64(2):936-9 PMID: 7530297
  102. Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study.
    J Neurochem. 1993 Oct;61(4):1369-75 PMID: 8104232
  103. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate.
    Eur J Pharmacol. 1985 Dec 10;119(1-2):127-8 PMID: 3002815
  104. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis.
    J Neurochem. 1994 Jan;62(1):134-46 PMID: 8263513
  105. EPR kinetic studies of superoxide radicals generated during the autoxidation of 1-methyl-4-phenyl-2,3-dihydropyridinium, a bioactivated intermediate of parkinsonian-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    J Biol Chem. 1992 Nov 25;267(33):23601-8 PMID: 1331093
  106. The MPTP-treated mouse as a model of parkinsonism: how good is it?
    Neurochem Int. 1992 Mar;20 Suppl:299S-303S PMID: 1365446
  107. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine.
    Brain Res. 1992 May 29;581(2):237-43 PMID: 1356579
  108. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice.
    Brain Res. 1992 Oct 2;592(1-2):74-83 PMID: 1360317
  109. Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) and derivatives.
    J Neural Transm Suppl. 1995;46:275-81 PMID: 8821064
  110. Mechanisms of action of 6-hydroxydopamine.
    Biochem Pharmacol. 1975 Jan 1;24(1):1-8 PMID: 1092302
  111. Acute effects of 1-methyl-1,4-phenylpyridinium ion (MPP+) on purine metabolism in rat striatum studied in vivo using the microdialysis technique.
    Brain Res. 1989 Mar 27;483(1):184-7 PMID: 2784990
  112. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.
    Brain Res. 1991 Dec 13;567(1):127-32 PMID: 1815820
  113. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
    Neuropharmacology. 1989 Oct;28(10):1089-97 PMID: 2510050
  114. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
    Neuropharmacology. 1987 Sep;26(9):1431-40 PMID: 3670563
  115. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme.
    Biochemistry. 1975 Dec 2;14(24):5294-9 PMID: 49
  116. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
    Brain Res. 1990 Jun 11;519(1-2):266-76 PMID: 1975765
  117. Effect of D1 receptor stimulation in normal and MPTP monkeys.
    Neurosci Lett. 1989 Sep 25;104(1-2):223-8 PMID: 2573015
  118. Antiparkinsonian actions of glutamate antagonists--alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms.
    J Neural Transm Park Dis Dement Sect. 1995;10(2-3):141-85 PMID: 9620061
  119. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons.
    J Pharmacol Exp Ther. 1970 Sep;174(3):413-20 PMID: 5456173
  120. Toward an understanding of the molecular mechanisms of physiological cell death.
    Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):786-9 PMID: 8430086
  121. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes.
    Exp Neurol. 1992 Feb;115(2):193-9 PMID: 1735466
  122. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
    Neuroscience. 1989;33(2):323-31 PMID: 2622529
  123. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.
    Pharmacol Biochem Behav. 1980 Feb;12(2):185-8 PMID: 7189592
  124. Does an endogenous methylpyridinium analogue cause Parkinson's disease?
    J Pharm Pharmacol. 1985 Sep;37(9):679-80 PMID: 2867199
  125. Role of dopamine in the neurotoxic effects of methamphetamine.
    J Pharmacol Exp Ther. 1985 Jun;233(3):539-44 PMID: 2409267
  126. Determination of the (R)- and (S)-enantiomers of salsolinol and N-methylsalsolinol by use of a chiral high-performance liquid chromatographic column.
    J Chromatogr B Biomed Appl. 1995 Aug 4;670(1):47-54 PMID: 7493084
  127. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons.
    Biochem Biophys Res Commun. 1991 Dec 31;181(3):1442-8 PMID: 1764096
  128. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity.
    Brain Res. 1991 Nov 15;564(2):256-60 PMID: 1810626
  129. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors.
    Nature. 1995 Oct 5;377(6548):424-8 PMID: 7566118
  130. Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion.
    J Neurochem. 1994 Aug;63(2):640-8 PMID: 8035188
  131. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice.
    Neuroreport. 1995 Mar 7;6(4):621-5 PMID: 7605913
  132. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains.
    Biochem Biophys Res Commun. 1987 Apr 29;144(2):1084-9 PMID: 3579928
  133. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.
    Brain Res. 1990 Oct 29;531(1-2):242-52 PMID: 1981162
  134. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
    Neuropharmacology. 1989 Nov;28(11):1271-3 PMID: 2687716
  135. Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents.
    J Neurochem. 1988 Jan;50(1):202-8 PMID: 2891784
  136. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds.
    J Neurochem. 1993 Oct;61(4):1191-206 PMID: 8376979
  137. Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
    J Neural Transm Park Dis Dement Sect. 1993;6(1):45-52 PMID: 8105797
  138. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin.
    Neurochem Int. 1996 Jan;28(1):41-9 PMID: 8746763
  139. Calcium in the brain under physiological and pathological conditions.
    Eur Neurol. 1990;30 Suppl 2:3-9; discussion 39-41 PMID: 2180715
  140. Glutathione peroxidase activity in Parkinson's disease brain.
    Neurosci Lett. 1985 Aug 5;58(3):343-6 PMID: 4047494
  141. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
    Neuroscience. 1993 Mar;53(1):169-78 PMID: 8469305
  142. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels.
    Eur J Pharmacol. 1976 Apr;36(2):363-71 PMID: 6286
  143. Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations.
    J Neural Transm Park Dis Dement Sect. 1991;3(1):73-8 PMID: 1905937
  144. Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity.
    Neurotoxicology. 1995 Fall;16(3):469-77 PMID: 8584278
  145. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine.
    Eur J Pharmacol. 1995 Jul 14;280(3):251-6 PMID: 8566093
  146. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.
    Brain Res. 1970 Dec 18;24(3):485-93 PMID: 5494536
  147. Serotonergic sprouting in primate MTP-induced hemiparkinsonism.
    Exp Brain Res. 1993;96(1):100-6 PMID: 7902292
  148. N-methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol, in rat brains: in vivo microdialysis study.
    J Neurochem. 1992 Aug;59(2):395-400 PMID: 1629715
  149. MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes.
    Free Radic Biol Med. 1993 Aug;15(2):181-6 PMID: 8397143
  150. Changes in lipid peroxidation induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in mouse brain homogenates.
    Neurosci Lett. 1987 Jun 26;77(3):321-6 PMID: 3497366
  151. Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs.
    Drug Alcohol Depend. 1979 Sep;4(5):435-8 PMID: 510182
  152. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
    Eur J Pharmacol. 1993 Jan 12;230(2):177-85 PMID: 8422900
  153. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
    Brain Res. 1990 Oct 1;528(2):181-8 PMID: 2271921
  154. In vivo monoamine oxidase inhibition by d-amphetamine.
    Biochem Pharmacol. 1980 May 15;29(10):1347-54 PMID: 6901611
  155. Striatal dopaminergic toxicity following intranigral injection in rats of 2-methyl-norharman, a beta-carbolinium analog of N-methyl-4-phenylpyridinium ion (MPP+).
    Neurosci Lett. 1989 Nov 6;105(3):344-9 PMID: 2594220
  156. Toxic effects of iron for cultured mesencephalic dopaminergic neurons derived from rat embryonic brains.
    J Neurochem. 1992 Jul;59(1):118-27 PMID: 1613493
  157. Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids.
    Adv Neurol. 1996;69:177-94 PMID: 8615127
  158. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Neuroscience. 1991;41(2-3):507-23 PMID: 1870701
  159. Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice.
    J Pharmacol Exp Ther. 1991 Feb;256(2):506-12 PMID: 1671596
  160. Salsolinol and catecholamines in human brain and their relation to alcoholism.
    Prog Clin Biol Res. 1982;90:57-67 PMID: 7111326
  161. Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal.
    Mov Disord. 1994 Mar;9(2):125-38 PMID: 8196673
  162. The role of environmental toxins in the etiology of Parkinson's disease.
    Trends Neurosci. 1989 Feb;12(2):49-54 PMID: 2469210
  163. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP.
    Brain Res. 1990 Sep 10;527(1):7-20 PMID: 1980841
  164. Effects of pargyline and pyrogallol on the methamphetamine-induced dopamine depletion.
    Mol Chem Neuropathol. 1995 Jan;24(1):31-41 PMID: 7755845
  165. A new experimental model of hypokinesia.
    Adv Neurol. 1974;5:427-32 PMID: 4440588
  166. A radical hypothesis for neurodegeneration.
    Trends Neurosci. 1993 Nov;16(11):439-44 PMID: 7507613
  167. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings).
    J Neural Transm. 1975;37(2):175-82 PMID: 1185162
  168. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains.
    J Neurochem. 1989 Feb;52(2):515-20 PMID: 2911028
  169. Inhibition of mitochondrial succinate oxidation--similarities and differences between N-methylated beta-carbolines and MPP+.
    Arch Biochem Biophys. 1992 May 1;294(2):539-43 PMID: 1314543
  170. The protective effect of 1-tert.butyl-4,4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Life Sci. 1985 Sep 30;37(13):1195-200 PMID: 2413325
  171. Chronic administration of MPTP to monkeys: behavioural morphological and biochemical correlates.
    Neurochem Int. 1992 Mar;20 Suppl:279S-285S PMID: 1365443
  172. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys.
    Drug Alcohol Depend. 1976 Feb;1(3):215-9 PMID: 828106
  173. Studies of the potentially endogenous toxin TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) in neuronal and glial cell cultures.
    J Neural Transm Suppl. 1995;46:255-63 PMID: 8821062
  174. N-methyl-D-aspartate receptor antagonist MK-801 induced circling behavior in rats with unilateral striatal ischemic lesions or nigral 6-hydroxydopamine lesions.
    Acta Neuropathol. 1993;86(5):480-3 PMID: 8310798
  175. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment.
    Brain Res. 1986 Jun 18;376(1):117-24 PMID: 3487376
  176. The pharmacology of (-)deprenyl.
    J Neural Transm Suppl. 1986;22:75-89 PMID: 3097262
  177. Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system.
    J Neural Transm Gen Sect. 1994;98(2):107-18 PMID: 7734108
  178. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-Hydroxydopamine.
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1968;261(3):271-88 PMID: 4387076
  179. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.
    Proc Natl Acad Sci U S A. 1990 Dec;87(23):9368-72 PMID: 2251279
  180. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study.
    Brain Res. 1980 Jul 7;193(1):153-63 PMID: 7378814
  181. MPTP-induced parkinsonism.
    Prog Neurobiol. 1990;34(2):107-14 PMID: 2181530
  182. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    J Pharmacol Exp Ther. 1975 Dec;195(3):453-64 PMID: 489
  183. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates.
    Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):586-92 PMID: 7907775
  184. Dissociation between biochemical and behavioral recovery in MPTP-treated mice.
    Pharmacol Biochem Behav. 1989 Sep;34(1):113-7 PMID: 2696981
  185. The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons.
    J Neural Transm Suppl. 1995;46:235-44 PMID: 8821060
  186. The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets.
    Neuropharmacology. 1992 Jul;31(7):713-5 PMID: 1357577
  187. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin.
    J Neural Transm Suppl. 1994;41:197-205 PMID: 7931227
  188. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
    Nature. 1991 Jan 31;349(6308):414-8 PMID: 1846943
  189. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
    J Neurol Sci. 1973 Dec;20(4):415-55 PMID: 4272516
  190. Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B.
    Neurochem Res. 1992 Aug;17(8):791-6 PMID: 1641061
  191. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease.
    J Neurochem. 1994 Nov;63(5):1987-90 PMID: 7931358
  192. 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity.
    Life Sci. 1987 Feb 23;40(8):731-40 PMID: 3492652
  193. Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens.
    Brain Res. 1994 Apr 18;643(1-2):276-81 PMID: 7518327
  194. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset.
    Eur J Pharmacol. 1990 May 31;181(1-2):97-103 PMID: 2117541
  195. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain.
    J Neurochem. 1970 Feb;17(2):269-78 PMID: 5494056
  196. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra.
    J Neurochem. 1989 Sep;53(3):692-7 PMID: 2760616
  197. Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehyde or diethyldithiocarbamate.
    Neurochem Int. 1992 Mar;20 Suppl:287S-293S PMID: 1365444
  198. Developing a stable bilateral model of parkinsonism in rhesus monkeys.
    Neuroscience. 1993 Jan;52(1):7-16 PMID: 8433810
  199. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes.
    Arch Biochem Biophys. 1992 May 15;295(1):132-6 PMID: 1575509
  200. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine.
    Brain Res. 1980 Jan 6;181(1):151-60 PMID: 7350950
  201. NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
    Neurosci Lett. 1992 Aug 17;142(2):179-82 PMID: 1280793
  202. Decreased dopamine in the retinas of patients with Parkinson's disease.
    Invest Ophthalmol Vis Sci. 1990 Nov;31(11):2473-5 PMID: 2243012
  203. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Proc Natl Acad Sci U S A. 1983 Jul;80(14):4546-50 PMID: 6192438
  204. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles.
    Biochem Biophys Res Commun. 1990 Aug 16;170(3):1049-55 PMID: 2167668
  205. The neuropathologic basis of different clinical subgroups of Parkinson's disease.
    J Neuropathol Exp Neurol. 1991 Nov;50(6):743-55 PMID: 1748881
  206. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity.
    Ann Neurol. 1993 Nov;34(5):715-23 PMID: 8239566
  207. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC.
    Eur J Pharmacol. 1988 Apr 13;148(3):327-34 PMID: 3384000
  208. On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats.
    Acta Neurol Scand Suppl. 1972;50:3-66 PMID: 4565013
  209. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.
    Brain Res. 1992 Feb 14;572(1-2):224-31 PMID: 1611516
  210. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
    Science. 1983 Feb 25;219(4587):979-80 PMID: 6823561
  211. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
    Neurosci Lett. 1985 Dec 18;62(3):389-94 PMID: 3912685
  212. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
    Ann Neurol. 1992 Feb;31(2):119-30 PMID: 1349466
  213. Morphine versus haloperidol catalepsy in the rat: a behavioral analysis of postural support mechanisms.
    Brain Res. 1980 Nov 10;201(1):143-72 PMID: 7191346
  214. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
    Psychopharmacol Bull. 1984 Summer;20(3):548-53 PMID: 6332333
  215. CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.
    J Neural Transm Suppl. 1978;(14):121-31 PMID: 39974
  216. Iron induces degeneration of nigrostriatal neurons.
    Brain Res Bull. 1992 Apr;28(4):645-9 PMID: 1617450
  217. Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism.
    Clin Neuropharmacol. 1991 Aug;14(4):359-66 PMID: 1913702
  218. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
    Neurosci Lett. 1992 Aug 17;142(2):128-30 PMID: 1454205
  219. Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-beta-carbolines?
    Biochem J. 1993 May 1;291 ( Pt 3):673-6 PMID: 8489493
  220. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine.
    Eur J Pharmacol. 1995 Mar 16;292(3-4):329-32 PMID: 7796873
  221. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
    Neurosurgery. 1995 Oct;37(4):733-9; discussion 739-41 PMID: 8559303
  222. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat.
    Neurosci Lett. 1993 Oct 29;161(2):121-3 PMID: 7903798
  223. Tremor produced by drugs.
    Nature. 1956 Jun 30;177(4522):1238 PMID: 13334520
  224. Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Acta Neuropathol. 1993;85(4):404-13 PMID: 7683168
  225. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence.
    Brain Res. 1989 Jan 2;476(1):10-5 PMID: 2492442
  226. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
    J Neural Transm Park Dis Dement Sect. 1991;3(2):99-108 PMID: 1716907
  227. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.
    Mol Chem Neuropathol. 1991 Jun;14(3):153-97 PMID: 1958262
  228. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.
    Brain Res. 1991 May 3;547(2):181-9 PMID: 1679365
Article Info
Journal
Journal of neural transmission (Vienna, Austria : 1996)
Abbr.
J Neural Transm (Vienna)
ISSN
0300-9564
Published
1996-00-00
Pages
987-1041
Language
English
Region
Austria
NLM ID
9702341
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com